Mebendazole †Rx

Repurposed Rx: Tubulin disruptor, VEGF ↓, apoptosis ↑; phase I/II active in glioma/ovarian/colorectal; chemo synergies.

AI extractedhuman reviewedsources checkedretractions suppressed

👥⭐⭐⭐ Moderate — Robust preclinical data; phase I/II trials show safety and signals in glioma/ovarian; larger RCTs ongoing.MBZVermoxEmverm

Forms: Oral tablets (100 mg, 500 mg chewable) · Compounded suspension

Educational only, not medical advice. OncoForge makes no claim that Mebendazole †Rx treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.

Key Takeaway

Anthelmintic repurposed for oncology: Potent tubulin disruptor with anti-angiogenic and pro-apoptotic actions; strong preclinical efficacy and emerging phase I/II signals, particularly in brain and gynecologic cancers.

Evidence at a glance

Tier 2 · animalGliomaOvarianColorectalProstatePancreatic

Extensive in vitro/in vivo validation; phase I/II trials confirm safety/PK and signals in glioma (NCT01729260), ovarian (NCT03925662); synergies with TMZ/cisplatin; ongoing 2025 trials in H&N/pancreatic.

How it may work

Mebendazole (MBZ) inhibits microtubule polymerization by binding β-tubulin, disrupting mitosis and inducing G2/M arrest; suppresses VEGF/HIF-1α signaling for anti-angiogenic effects; activates intrinsic apoptosis via caspase-3/9, Bax upregulation, and p53 stabilization; additional targets include Hedgehog, NF-κB, and kinase pathways; penetrates BBB effectively; preclinical and early clinical data in glioma, ovarian, colorectal, and other solid tumors.

Targets & pathways

Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.

Tubulin↓Microtubule polymerization inhibition → mitotic arrest
Angiogenesis↓VEGF/HIF-1α suppression
Apoptosis↑Caspase activation, p53 stabilization
Hedgehog↓SMO inhibition in some models
NF-κB↓Inflammation and survival signaling ↓

TubulinAngiogenesisApoptosis

Often studied / combined with

Combinations reported in the literature, not a protocol or a recommendation.

Temozolomide: Improved PFS/OS in recurrent glioma phase II.
Cisplatin: Reverses resistance, boosts apoptosis in ovarian PDX.
Docetaxel: Synergistic microtubule disruption in prostate/ACC models.
Curcumin: Enhanced NF-κB/apoptosis inhibition in colorectal.

Overlapping mechanisms

Tubulin: Overlaps with taxanes/vinca; potential additive neuropathy.
Angiogenesis: May amplify with bevacizumab; monitor vascular events.

Safety & interactions

Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.

Risk categories

HepatotoxicityGi UpsetNeutropenia

Potential interactions

CYP3A4 inducersMonitorModerateTheoreticalReduces MBZ levels (e.g., rifampin, carbamazepine).
CYP3A4 inhibitorsCautionModerateTheoreticalIncreases exposure (e.g., ketoconazole).
TemozolomideSynergizeLowTheoreticalAdditive BBB penetration and anti-glioma effects.

Timing

With-fatty-meal: Boosts absorption up to 300%.
BID: Divided for steady-state levels.

References

Research

No published studies for Mebendazole yet

New studies appear here once they’ve been reviewed. Browse all studies.

Dose: as studied, not a recommendation

These are doses as studied or reported, never a recommendation. The right amount of Mebendazole †Rx depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.

Ranges seen in adjunct / practice use: 100–1500 mg/day (po) divided BID-TID; with fatty meal for absorption, Anti-parasitic 100 mg BID; oncology trials 200-500 mg BID (up to 1500 mg/day in glioma); fatty food increases bioavailability 2-3x..

Trials studying Mebendazole †Rx

No actively-recruiting trials matched right now. Recruiting is not the same as proven. Search ClinicalTrials.gov →

Appears in these protocol claims

Mebendazole †Rx is named in these protocols discussed online. Listed for transparency: being part of a protocol is not evidence that it works, and OncoForge does not endorse them.

Ivermectin / Benzimidazole Protocol Claims : Aggressive online protocols combining ivermectin with fenbendazole or mebendazole.
Jane McLelland / Metabolic Blocking Claims : Multi-pathway metabolic strategy based around starving cancer fuel routes and blocking escape pathways.
Care Oncology-Style Repurposed Drug Claims : Clinic-associated repurposed-drug approach often discussed around four common medications.

Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.

← All agents · Research Radar